Medivation

Acadia Announces Additions to Executive Team

Retrieved on: 
Wednesday, January 31, 2024

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced two new appointments to its executive team.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced two new appointments to its executive team.
  • Following a transition period, Austin D. Kim, Executive Vice President, General Counsel and Secretary will be leaving Acadia to pursue other opportunities.
  • “I’m thrilled to announce these two important additions to the team,” said Steve Davis, Chief Executive Officer.
  • “Jennifer brings strong executive leadership skills with over 20 years of legal, strategy and business experience at emerging, rapidly growing and Fortune 500 life sciences companies.

Sail Biomedicines Appoints Tech and Pharma Industry Veteran Frank D’Amelio to Its Board

Retrieved on: 
Thursday, January 4, 2024

Mr. D’Amelio brings to Sail’s board an accomplished record as a technology and pharmaceutical operations, finance and global supply executive.

Key Points: 
  • Mr. D’Amelio brings to Sail’s board an accomplished record as a technology and pharmaceutical operations, finance and global supply executive.
  • At Lucent, he played a critical role in its spinout from AT&T.
  • “I’m honored to be joining the Sail Biomedicines Board of Directors at a pivotal time for the company,” said Mr. D’Amelio.
  • “Sail’s vision and platform, which builds on over eight years of experimentation, represents an exciting opportunity to generate new medicines and forge innovative relationships with partners.

Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

Retrieved on: 
Wednesday, August 23, 2023

Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer.
  • She joins Exelixis as the company accelerates development of its product pipeline and builds on the success of its global cabozantinib oncology franchise.
  • Most recently, Dr. Peterson was at CytomX, first as Executive Vice President and Chief Development Officer and then as President and Chief Operating Officer.
  • “It’s a pleasure to welcome Dr. Amy Peterson to Exelixis as the company’s next Chief Medical Officer.

Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer

Retrieved on: 
Tuesday, June 13, 2023

and NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced the promotion of Melanie Morrison from Senior Vice President, Development Operations to Chief Development Officer.

Key Points: 
  • and NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced the promotion of Melanie Morrison from Senior Vice President, Development Operations to Chief Development Officer.
  • As Chief Development Officer, Ms. Morrison leads the Company’s clinical operations, program management and program leadership functions, and regulatory affairs.
  • She has played an integral part in our Phase 1 trial for BDTX-1535 in non-small cell lung cancer and glioblastoma and I am extremely pleased to announce her well-deserved promotion to Chief Development Officer.
  • Ms. Morrison joined Black Diamond in October 2022 with over two decades of experience in clinical operations, program management, product leadership and other key development functions in addition to driving corporate transitions from early to late-stage development at several biopharmaceutical companies.

Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

Retrieved on: 
Wednesday, May 17, 2023

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors.
  • “Sarah is an accomplished healthcare executive with extensive global clinical development and corporate strategy experience,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus.
  • She has significant experience designing and leading rare disease programs from discovery to global regulatory approvals and commercialization.
  • “Marinus has emerged as a leader in the development of innovative treatment options for patients with genetic epilepsies and seizure disorders.

Cumulus Neuroscience Receives FDA 510(k) Clearance for Award-Winning, First-In-Class Neurophysiology Platform for At-Home Use

Retrieved on: 
Thursday, May 4, 2023

BELFAST, Northern Ireland and CAMBRIDGE, Mass., May 4, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, today announced that its novel, award-winning dry-sensor EEG headset, has been granted 510(k) clearance from the United States Food and Drug Administration (FDA). This represents the second medical device clearance for the headset, which previously received the UK Conformity Assessed (UKCA) mark in the United Kingdom.  

Key Points: 
  • This represents the second medical device clearance for the headset, which previously received the UK Conformity Assessed (UKCA) mark in the United Kingdom.
  • This groundbreaking technology provides a means to initiate clinical studies remotely with data transmitted to the Cumulus Medical Device Hub, allowing healthcare professionals to review EEG recordings in real-time.
  • The company's 510(k) clearance comes on the heels of its appointment of Tina Sampath as Chief Commercial Officer (CCO).
  • Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function.

Cumulus Neuroscience Receives FDA 510(k) Clearance for Award-Winning, First-In-Class Neurophysiology Platform for At-Home Use

Retrieved on: 
Thursday, May 4, 2023

BELFAST, Northern Ireland and CAMBRIDGE, Mass., May 4, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, today announced that its novel, award-winning dry-sensor EEG headset, has been granted 510(k) clearance from the United States Food and Drug Administration (FDA). This represents the second medical device clearance for the headset, which previously received the UK Conformity Assessed (UKCA) mark in the United Kingdom.  

Key Points: 
  • This represents the second medical device clearance for the headset, which previously received the UK Conformity Assessed (UKCA) mark in the United Kingdom.
  • This groundbreaking technology provides a means to initiate clinical studies remotely with data transmitted to the Cumulus Medical Device Hub, allowing healthcare professionals to review EEG recordings in real-time.
  • The company's 510(k) clearance comes on the heels of its appointment of Tina Sampath as Chief Commercial Officer (CCO).
  • Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function.

Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors

Retrieved on: 
Monday, March 27, 2023

"We welcome Mohammad to our Board at an exciting time for Aadi, as we advance the development of FYARRO for unmet clinical needs beyond our approved indication of PEComa.

Key Points: 
  • "We welcome Mohammad to our Board at an exciting time for Aadi, as we advance the development of FYARRO for unmet clinical needs beyond our approved indication of PEComa.
  • Mohammad is a world-class clinical development leader in oncology and will be a great complement to our board and partner with our highly experienced team," said Caley Castelein, M.D., Aadi Board Chairman.
  • "Mohammad has been instrumental in the development of Medivation's Xtandi and Welireg (belzutifan), when at Peloton Therapeutics.
  • "I am excited to join Aadi's Board of Directors in their mission to unlock the potential of nab-sirolimus in addressing mTOR-driven diseases," said Dr. Hirmand.

Nutcracker Therapeutics Appoints Industry Veteran Angela Peters as Chief Human Resources Officer

Retrieved on: 
Tuesday, March 7, 2023

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the appointment of Angela Peters as the company’s first Chief Human Resources Officer (CHRO).

Key Points: 
  • Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the appointment of Angela Peters as the company’s first Chief Human Resources Officer (CHRO).
  • “I am particularly excited to come aboard at this important inflection point for the company, as it unlocks the powerful potential of RNA therapeutics.
  • “Angela brings extensive experience, alongside a proven track record of elevating and transforming internal operations across the biotech industry,” said Igor Khandros, CEO.
  • Peters joins several other key C-suite hires within the past year, including Chief Medical Officer Dr. Robert Schott, Chief Operating Officer Dr. John Stubenrauch, and Chief Business Officer Dr. Geoff Nosrati.

Metagenomi Appoints Sarah Noonberg, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Tuesday, February 14, 2023

Metagenomi , a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, today announced the appointment of Sarah Noonberg, M.D., Ph.D. as Chief Medical Officer.

Key Points: 
  • Metagenomi , a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, today announced the appointment of Sarah Noonberg, M.D., Ph.D. as Chief Medical Officer.
  • In this role, Dr. Noonberg will oversee the clinical development of Metagenomi’s drug candidates and development strategy of the Company’s expanding therapeutic pipeline.
  • “Dr.
  • Earlier, she was Chief Medical Officer of Nohla Therapeutics, leading clinical development of a program for hematologic malignancies.